First anti-aging aftershave helps prevent onset of new facial lines, helps restore youthful appearance

DermaLastyl-m Aftershave aids in preventing the onset of new facial lines in men.

(EMAILWIRE.COM, May 09, 2008 ) New York – The first and only anti-wrinkle, anti-aging aftershave, DermaLastyl-m, is now available. Using genuine human elastin, Elastatropin, to help decrease the appearance of existing wrinkles and restore youthful appearance, DermaLastyl-m Aftershave aids in preventing the onset of new facial lines. Independent studies of the DermaLastyl patented delivery system note significant uptake of synthetic human elastin into the outer skin layers. Men can reduce their need to schedule wrinkle-eradicating risky injections and surgical procedures by using the new DermaLastyl-m Aftershave.



The primary active ingredient is a complex chain of over 600 amino acids. Such complex molecules are normally too large to work in a topical cosmetic application. Even the most advanced cosmetics sold contain much smaller peptide combinations totaling six amino acids at most. DermaLastyl-m is not yet in stores but can be purchased online at http://www.dermalastyl-m.com/ or by calling 800-335-8312. Distribution will be expanded to include retail and department stores worldwide in the coming months.



About DermaPlus, Inc.

DermaPlus, Inc., the producer of DermaLastyl line of products, is a biotechnology company that designs and manufactures sophisticated, high performance biomaterials for use in cosmeceuticals. Based on human genetic sequences, these biomaterials can be customized to reflect the genetic makeup of human tissues, population groups or even single individuals. DermaLastyl-B, DermaLastyl-E, DermaLastyl-Bx, DermaLastyl-Ex, Keracyte-b, and DermaLastyl-m are the first genetically engineered products on the market that help restore elastin properties to the skin. Used properly, DermaLastyl will eliminate and/or prevent wrinkles reducing the need or extending the life of cosmetic medical procedures such as Botox injections or facelifts.



Media Contact:

Jerry Jennings

Emerson Gerard Associates

561-881-7318

mediareply@emersongerard.com


###

This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution for $499/year, go to http://www.emailwire.com